Compare CLMT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | ZYME |
|---|---|---|
| Founded | 1916 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2024 | 2022 |
| Metric | CLMT | ZYME |
|---|---|---|
| Price | $28.58 | $22.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $23.25 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.4M | 630.3K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.39 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,137,100,000.00 | $105,965,000.00 |
| Revenue This Year | $4.45 | $162.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $7.68 | $9.03 |
| 52 Week High | $31.41 | $28.49 |
| Indicator | CLMT | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 43.81 |
| Support Level | $17.31 | $22.23 |
| Resistance Level | $30.67 | $23.66 |
| Average True Range (ATR) | 1.58 | 1.42 |
| MACD | -0.30 | -0.05 |
| Stochastic Oscillator | 44.01 | 9.06 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.